Key result
Angiotensin-converting enzyme gene polymorphisms have conflicting effects on renal disease pathogenesis and treatment response, meaning all patients should still be considered for ACE inhibitors.
Why the study?
Does angiotensin-converting enzyme genotyping assist in the assessment of prognosis and response to angiotensin-converting enzyme inhibitor treatment in patients with chronic renal disease?
Population
Patients with chronic renal disease
Design
Review
Authors
Loading...
Does not support ACE genotyping to guide renal disease therapy; leaves open whether higher-level evidence will clarify polymorphism effects.
Does angiotensin-converting enzyme genotyping assist in the assessment of prognosis and response to angiotensin-converting enzyme inhibitor treatment in patients with chronic renal disease?
Current evidence does not support the use of angiotensin-converting enzyme genotyping to guide therapy; all patients with chronic renal disease should be considered candidates for angiotensin-converting enzyme inhibitors regardless of genotype.
Maarten W. Taal (2000) conducted a review in renal disease. Angiotensin-converting enzyme gene polymorphisms was evaluated. Angiotensin-converting enzyme gene polymorphisms have conflicting effects on renal disease pathogenesis and treatment response, meaning all patients should still be considered for ACE inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: